The mandate as a working document: three buckets that define the universe, eight characteristics that define a candidate, a base rate of failure agreed in advance, and a two-question test for anyone selling you anything.
1. Define the universe with two or three business archetypes, before any screening
The repeatable method
- Choose a small number of structural categories that you believe produce durable excess returns, and refuse to look outside them.
- Support each with evidence, not preference — an academic result, a long-run study, or your own recorded base rate.
- Label every candidate with its category at the top of the analysis, so a name that fits none is rejected before the numbers start.
- Accept the cost: whole sectors become uninvestable, and that is the point.
Here: three buckets.
Owner-operator stocks — "companies that are still run by their founder", supported by "family companies and founder-led companies outperform the S&P500 with
3.7% per year and 3.9% per year respectively".
Monopolies and oligopolies — quoting
The Myth of Capitalism: "If he can't buy a monopoly, he'll buy a duopoly. And if he can't buy a duopoly, he'll settle for an oligopoly."
Cannibal stocks — heavy repurchasers; "Pay close attention to the cannibals." The labels are applied in practice:
ANET is tagged an Owner-Operator Stock on
14 May,
FICO an Oligopoly and a Cannibal on
21 May.
Watch for
- Cannibal status that is really dilution offset. A shrinking share count alongside a 22%-of-profit share-compensation bill is not the same thing.
- Founder-outperformance studies. The effect is real in the literature but selection-heavy, and the 3.7%/3.9% figures are quoted without a source.
2. Fix the candidate checklist and the mandate constraints in writing
The repeatable method
- Write down the characteristics every holding must have, and treat the list as a gate rather than a scorecard.
- Write down the portfolio constraints separately: geography, number of positions, turnover, and whether you will time the market.
- Also write the negative screen — who this strategy is not for — so that expectations are set before the first bad year.
- Date the document and revise it deliberately, not silently.
Here: eight characteristics — "sustainable competitive advantage, great management with skin in the game, healthy balance sheet, low capital intensity, good capital allocation, high profitability, plenty of reinvestment opportunities, trading at fair valuation levels". Five constraints — "developed countries only", "15–20 stocks", best companies in the world, "we won't trade a lot", "we won't try to time the market (I'm way too dumb for that)". Dated to the Owner's Manual of 2023 and restated unchanged here.
Watch for
- Constraints that drift without an announcement. The 1 September issue revisits exactly this — a stricter bar and a re-affirmed 15–20 stocks — which is how a mandate change should be done.
- "Fair valuation levels" as the eighth characteristic. It is the only subjective one, and it is where every disagreement in the archive actually lives.
3. Apply a two-question test to anyone recommending an investment product
The repeatable method
- Ask: are you invested in this yourself, with meaningful money?
- Ask: does this product have a long track record of beating a relevant benchmark?
- Proceed only on two clear yeses; treat a hedged answer to either as a no.
- Apply the same test to the person publishing the research you follow, including this one.
Here: "You should always ask him or her two questions: Are you invested in this product yourself? Does this investment product have a great track record? Only move forward when the answer is 'yes' on both questions. Spoiler alert: not too many bankers will pass both criteria." The author's own answer to the first is "I have all my investable assets invested in the companies I write about"; the answer to the second, for a portfolio started in 2023, is necessarily short.
Watch for
- The second test being the weaker one for a young strategy. Three years is inside the luck window the same author defines.
- Alignment as a substitute for skill. Someone can be fully invested alongside you and still be wrong.
4. Pre-commit to a base rate of failure so a bad outcome does not become a strategy change
The repeatable method
- Write down, in advance, how often you expect things to go wrong: market drawdowns, individual disappointments, years of underperformance.
- When one occurs, check it against the pre-committed rate before concluding anything about the process.
- Only revisit the strategy when the realised rate exceeds the expected one over a meaningful sample.
- Publish the rate, so that neither you nor your readers can retrospectively pretend to have expected better.
Here: François Rochon's rule of three — "
One year out of three, the stock market will go down at least 10%. One stock out of three that we buy will be a disappointment. One year out of three, we will underperform the index." With the honest corollary: "It's fair to say that I will keep making investment mistakes going forward. The most important thing is to minimize them as much as possible." The same frame is used
five days later to frame an actual sale.
Watch for
- A base rate used as pre-emptive cover. It explains one loss in three; it does not explain three losses in three.
- Whether the realised rate is ever measured against the stated one. It is not, in this archive.
5. Publish the mistakes by type, not just by name
The repeatable method
- Keep a running list of decisions that went wrong, with the date and the original reasoning.
- Classify each: was it a buying error, a selling error, or a reasoning error — a good decision with a bad outcome?
- Look for the repeated type. The category that recurs is the process defect; the individual names are noise.
- Act on the ones where the conclusion has already been reached, and say so when you are not acting.
Here: three mistakes, and usefully three different types.
ULTA — a
selling error: "sold March 2025. The stock is up +50% since then."
JDG.L — a
buying error, acted on
five days later.
NVO — a
reasoning error: "buying Novo Nordisk
because I thought the stock was cheap", where the flaw named is the criterion, not the company, and nothing is sold.
Watch for
- Selling errors going unrecorded elsewhere. They never appear in a portfolio statement, so only a written list catches them.
- A name appearing as both a "steal" and a "mistake" within 48 hours, as Novo does here and on 24 May. Both can be true; the reader needs the reconciliation stated.
6. Never let cheapness be the reason for a purchase
The repeatable method
- Write the one-line reason for every purchase before you place the order.
- If that sentence is about the price rather than the business, stop — cheapness is a permission, not a thesis.
- Require an independent statement of why the business will be worth more in ten years.
- Review purchase rationales periodically as a group, looking for the ones that were price-led.
Here: "
Buying Novo Nordisk because I thought the stock was cheap. Up until now, the stock only became cheaper." It is the sharpest self-criticism in the archive because it indicts a method rather than a name — and because the same portfolio's core discipline elsewhere is precisely valuation-led. The counterweight is the
Arista pass, where a superb business was declined on price alone.
Watch for
- Value traps generally: a falling multiple on falling estimates is not getting cheaper.
- The mirror error. Declining wonderful businesses purely on price is also price-led thinking, and the archive does that too.
7. Judge a research product by its capacity, not only its ideas
The repeatable method
- Establish who does the work, how much of it, and whether the output volume is sustainable by that person.
- Check whether the deep research is original or syndicated from guests, and whether that is disclosed.
- Ask what happens to the product if the individual stops — key-person risk applies to newsletters as much as to companies.
- Weigh disclosed effort as evidence of diligence, but not as evidence of accuracy.
Here: the routine is disclosed unusually plainly — "
a 13.5 hour working day. Every. Single. Day. I work 7 days out of 7", no meetings before 3pm, a fixed daily structure, credited to
Atomic Habits,
Eat That Frog and
Deep Work. Against that, the
21 May 114-page FICO case was written by a guest, and the
19 May Fairfax study is disclosed as reading a book and a thousand pages of letters. Both are the right disclosures to make.
Watch for
- Output volume as a proxy for quality. Two issues a week is a publishing schedule, and schedules generate content whether or not there is something to say.
- The author's own caveat, which is the honest one: "The most important thing at the end of your life is not how much you worked."
Methods distilled from the archived Compounding Quality post for personal study. Not investment advice.